Efficacy of Ruxolitinib cream
Ruxolitinib cream demonstrated effective anti-inflammatory and antipruritic efficacy in a Phase 2 study of adults with atopic dermatitis (AD). In the evaluation of Ruxolitinib Cream in Atopic Dermatitis Studies 1 and 2, 631 and 618 patients were randomized. At week 8, significantly more patients achieved assessed treatment success with ruxolitinib cream 0.75% (50.0%/39.0%) and ruxolitinib cream 1.5% (53.8%/51.3%) compared with vehicle. Within 12 hours after the first application of 1.5% ruxolitinib cream, the itching was significantly reduced (P<0.05). Application site reactions were rare (<1%). Ruxolitinib cream is more effective than vehicle and is well tolerated.
In two major studies, ruxolitinib cream improved pigmentation compared with placebo. The primary measure of effectiveness is the proportion of patients with at least a 75% improvement in facial pigmentation as measured by the Facial Vitiligo Standard Score (F-VASI75) after 6 months. The two studies involved a total of 661 patients with non-segmental vitiligo. On average, about 31% of patients treated with Opsura experienced at least a 75% improvement in facial pigmentation after 6 months of treatment. Using a standardized score for total body pigmentation (T-VASI50), the study further showed that after 6 months, 22% of patients using ruxolitinib cream had at least a 50% improvement in total body pigmentation.
The original drug of ruxolitinib cream has not yet been marketed in China, so it cannot be included in medical insurance. The price of ruxolitinib cream Original drug, specificationsinn 1.5%*60g, which is marketed overseas, is around RMB 20,000 per tube (the price may fluctuate due to the exchange rate), which is relatively expensive. The price of generic ruxolitinib cream marketed overseas is relatively cheap, and its pharmaceutical ingredients are basically the same as those of the original drug. The price of the specificationinn 1.5%*30g produced by a Bangladesh pharmaceutical factory is around 600 yuan per tube (the price may fluctuate due to exchange rate effects).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)